Histamine Receptor Blockade Stops Peanut-Induced Response

This article originally appeared here.
Share this content:
Histamine Receptor Blockade Stops Peanut-Induced Response
Histamine Receptor Blockade Stops Peanut-Induced Response

WEDNESDAY, April 13, 2016 (HealthDay News) -- Blockade of histamine 1 (H1R) and 4 receptors (H4R) in peanut challenge can combine to prevent development of intestinal allergic responses, according to an experimental study published online April 5 in Allergy.

Meiqin Wang, M.D., Ph.D., from National Jewish Health in Denver, and colleagues examined the role of H1R and H4R in intestinal allergic responses in Balb/c mice that were sensitized and challenged to peanut. Mice were treated orally with the H1R antagonist loratadine and/or the H4R antagonist JNJ7777120 during the challenge phase. Dendritic cells (DCs) derived from bone marrow were adoptively transferred to nonsensitized wild-type mice.

The researchers found that individual loratadine or JNJ7777120 treatment partially suppressed diarrhea development and intestinal inflammation and correlated with a reduction in the numbers of DCs in mesenteric lymph nodes and lamina propria. Development of diarrhea and intestinal inflammation were prevented with combined treatment with both drugs. In vitro, the combination suppressed DC antigen presenting cell function to T helper cells as well as DC calcium mobilization and chemotaxis to histamine.

"Blockade of both H1R and H4R in the challenge phase had additive effects in preventing the intestinal consequences of peanut sensitization and challenge," the authors write. "These effects were mediated through limitation of mesenteric lymph node and intestinal DC accumulation and function."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

Insulin Glargine, Lixisenatide Combo Beneficial in T2DM

Insulin Glargine, Lixisenatide Combo Beneficial in T2DM

Improved achievement of glycemic targets, reduced body weight

European, American Guidelines Lead to Different Recs for Statins

European, American Guidelines Lead to Different Recs for ...

Quantification of CAC score can improve stratification for those at high, low risk for events

Hyperbaric O2 Therapy Effective in Maxillary Osteoradionecrosis

Hyperbaric O<sub>2</sub> Therapy Effective in Maxillary Osteoradionecrosis

Positive clinical outcome with HBOT for 85.7 percent of patients with maxillary bone osteoradionecrosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »